Artículos por temáticas

Leptin regulation of hippocampal synaptic function in health and disease

Irving AJ, Harvey J.

Philos Trans R Soc Lond B Biol Sci. 2013 Dec 2;369(1633):20130155. doi: 10.1098/rstb.2013.0155. Print 2014 Jan 5.

[Proposal of endogenous anticholinergic hypothesis in Alzheimer disease]

Hori K, Konishi K, Akita R, Tani M, Tomioka H, Kitajima Y, Yokoyama S, Azuma K, Ikuse D, Akashi N, Yuda H, Hachisu M.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2013 Jun;33(3):117-26.

[A case report of early-onset Alzheimer's disease with multiple psychotic symptoms, finally diagnosed as APPV717I mutation by genetic testing]

Ishimaru T, Ochi S, Matsumoto T, Yoshida T, Abe M, Toyota Y, Fukuhara R, Tanimukai S, Ueno S.

Seishin Shinkeigaku Zasshi. 2013;115(10):1042-50.

Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain

Sultana R, Perluigi M, Butterfield DA.

Free Radic Biol Med. 2013 Sep;62:157-169. doi: 10.1016/j.freeradbiomed.2012.09.027. Epub 2012 Oct 5.

Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications

Sabbagh JJ, Kinney JW, Cummings JL.

Neurobiol Aging. 2013 Jan;34(1):169-83. doi: 10.1016/j.neurobiolaging.2012.02.027. Epub 2012 Apr 1.

Prolonged running, not fluoxetine treatment, increases neurogenesis, but does not alter neuropathology, in the 3xTg mouse model of Alzheimer's disease

Marlatt MW, Potter MC, Bayer TA, van Praag H, Lucassen PJ.

Curr Top Behav Neurosci. 2013;15:313-40. doi: 10.1007/7854_2012_237.

[New risk genes for Alzheimer's disease--biomarkers predicting the disease?]

Hiltunen M, Haapasalo A, Soininen H.

Duodecim. 2013;129(6):583-8.

Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study

Miyoshi I, Fujimoto Y, Yamada M, Abe S, Zhao Q, Cronenberger C, Togo K, Ishibashi T, Bednar MM, Kupiec JW, Binneman B.

Int J Clin Pharmacol Ther. 2013 Dec;51(12):911-23. doi: 10.5414/CP201816.

Memantine-associated hyperkalaemia in a patient with Alzheimer's disease

Tsukamoto T, Yamada H, Uchimura N.

Psychogeriatrics. 2013 Sep;13(3):180-1. doi: 10.1111/psyg.12022.

Diffusion tensor imaging to determine effects of antidementive treatment on cerebral structural connectivity in Alzheimer's disease

Kilimann I, Likitjaroen Y, Hampel H, Teipel S.

Curr Pharm Des. 2013;19(36):6416-25. doi: 10.2174/1381612811319360003.

Missing data analysis in drug-naïve Alzheimer's disease with behavioral and psychological symptoms

Kwak YT, Yang Y, Park SG.

Yonsei Med J. 2013 Jul;54(4):825-31. doi: 10.3349/ymj.2013.54.4.825.

Adverse drug reactions in patients with Alzheimer's disease and related dementia in France: a national multicentre cross-sectional study

Laroche ML, Perault-Pochat MC, Ingrand I, Merle L, Kreft-Jais C, Castot-Villepelet A, Durrieu G, Gras V, Guy C, Jean-Pastor MJ, Jonville-Béra AP, Merlet-Chicoine I, Miremont-Salamé G, Nourhashemi F, C

Pharmacoepidemiol Drug Saf. 2013 Sep;22(9):952-60. doi: 10.1002/pds.3471. Epub 2013 Jun 24.

Mens sana in corpore sano revisited

Jeger RV.

Eur Heart J. 2013 Sep;34(33):2580-1. doi: 10.1093/eurheartj/eht244. Epub 2013 Jul 4.

Nature as a source of metabolites with cholinesterase-inhibitory activity: an approach to Alzheimer's disease treatment

Pinho BR, Ferreres F, Valentão P, Andrade PB.

J Pharm Pharmacol. 2013 Dec;65(12):1681-700. doi: 10.1111/jphp.12081. Epub 2013 May 16.

Dopamine D₂-agonist rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer's disease patients

Martorana A, Di Lorenzo F, Esposito Z, Lo Giudice T, Bernardi G, Caltagirone C, Koch G.

Neuropharmacology. 2013 Jan;64:108-13. doi: 10.1016/j.neuropharm.2012.07.015. Epub 2012 Aug 1.